Cargando…
Pixantrone, a new anticancer drug with the same old cardiac problems? An in vitro study with differentiated and non-differentiated H9c2 cells
Pixantrone (PIX) is an anticancer drug approved for the treatment of multiple relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. It is an aza-anthracenedione synthesized to have the same anticancer activity as its predecessors, anthracyclines (e.g. doxorubicin) and anthracenedione...
Autores principales: | Reis-Mendes, Ana, Alves, Marisa, Carvalho, Félix, Remião, Fernando, Bastos, Maria Lourdes, Costa, Vera Marisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Slovak Toxicology Society SETOX
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6117818/ https://www.ncbi.nlm.nih.gov/pubmed/30181708 http://dx.doi.org/10.2478/intox-2018-0002 |
Ejemplares similares
-
The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells
por: Reis-Mendes, Ana, et al.
Publicado: (2019) -
Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells
por: Pereira-Oliveira, Maria, et al.
Publicado: (2019) -
The role of inflammation and antioxidant defenses in the cardiotoxicity of doxorubicin in elderly CD-1 male mice
por: Reis-Mendes, Ana, et al.
Publicado: (2023) -
Pixantrone beyond monotherapy: a review
por: Barrenetxea Lekue, Cristina, et al.
Publicado: (2019) -
Pixantrone Sensitizes Gram-Negative Pathogens to Rifampin
por: She, Pengfei, et al.
Publicado: (2022)